Literature DB >> 29196283

Ringed telangiectasias: an unusual presentation of telangiectasia macularis eruptiva perstans.

Laila Siddique1, Hadjh Ahrns2, Elizabeth Seiverling2,3.   

Abstract

Telangiectasia macularis eruptiva perstans (TMEP) is a rare form of cutaneous mastocytosis. While most cutaneous mastocytoses occur in children and are asymptomatic, TMEP occurs predominantly in adults and is associated with systemic manifestations, requiring medical management. TMEP is typically characterised by scattered red-brown macules on the trunk and extremities, but must be differentiated from other telangiectatic conditions such as scleroderma, hereditary haemorrhagic telangiectasia and telangiectasias secondary to cirrhosis. Practitioners must be aware that variants to the classic presentation of TMEP exist, such as the ringed telangiectasias we describe. Diagnostic workup including tissue biopsy must be considered in such patients after a thorough history and physical have been performed and other telangiectatic processes have been ruled out. The treatment of cutaneous mastocytosis aims at controlling symptoms and preventing mast cell degranulation. Cosmetic treatment includes the use ofPsoralen and ultraviolet A (PUVA) therapy, total skin electron beam radiation and flashlamp pulsed-dye laser treatment. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  cirrhosis; dermatology; rheumatology; skin

Mesh:

Substances:

Year:  2017        PMID: 29196283      PMCID: PMC5720326          DOI: 10.1136/bcr-2017-221784

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  10 in total

Review 1.  Systemic mastocytosis.

Authors:  Cem Akin; Dean D Metcalfe
Journal:  Annu Rev Med       Date:  2004       Impact factor: 13.739

2.  Treatment of telangiectasia macularis eruptiva perstans with montelukast.

Authors:  R Cengizlier; S Hücümenoğlu; A Ozen; R Tülin Sayli
Journal:  Allergol Immunopathol (Madr)       Date:  2009 Nov-Dec       Impact factor: 1.667

Review 3.  Diagnostic criteria and classification of mastocytosis: a consensus proposal.

Authors:  P Valent; H P Horny; L Escribano; B J Longley; C Y Li; L B Schwartz; G Marone; R Nuñez; C Akin; K Sotlar; W R Sperr; K Wolff; R D Brunning; R M Parwaresch; K F Austen; K Lennert; D D Metcalfe; J W Vardiman; J M Bennett
Journal:  Leuk Res       Date:  2001-07       Impact factor: 3.156

4.  Cutaneous mastocytosis in adults. evaluation of 14 patients with respect to systemic disease manifestations.

Authors:  B Tebbe; P G Stavropoulos; K Krasagakis; C E Orfanos
Journal:  Dermatology       Date:  1998       Impact factor: 5.366

5.  Telangiectasia macularis eruptiva perstans.

Authors:  N F Gibbs; S F Friedlander; E F Harpster
Journal:  Pediatr Dermatol       Date:  2000 May-Jun       Impact factor: 1.588

6.  Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm.

Authors:  B J Longley; L Tyrrell; S Z Lu; Y S Ma; K Langley; T G Ding; T Duffy; P Jacobs; L H Tang; I Modlin
Journal:  Nat Genet       Date:  1996-03       Impact factor: 38.330

7.  Treatment of telangiectasia macularis eruptiva perstans with total skin electron beam radiation.

Authors:  Timothy P Monahan; Angelo A Petropolis
Journal:  Cutis       Date:  2003-05

8.  Treatment of telangiectasia macularis eruptiva perstans with the 585-nm flashlamp-pumped dye laser.

Authors:  D L Ellis
Journal:  Dermatol Surg       Date:  1996-01       Impact factor: 3.398

Review 9.  Cutaneous mastocytosis: a review focusing on the pediatric population.

Authors:  Laura D Briley; Charles M Phillips
Journal:  Clin Pediatr (Phila)       Date:  2008-05-23       Impact factor: 1.168

10.  Telangiectasia macularis eruptive perstans successfully treated with PUVA therapy.

Authors:  Eleni Sotiriou; Zoi Apalla; Demetris Ioannides
Journal:  Photodermatol Photoimmunol Photomed       Date:  2010-02       Impact factor: 3.135

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.